Medical Companies

Industry: Pharmaceuticals, Biotechnology
Target Discovery is a discovery biology company that seeks to alleviate critical bottlenecks imposed by current technologies upon drug development and life science research. The company is developing new platform technologies for the elucidation of high quality biological data and for the conversion of that information into a confirmed understanding of biological pathways. Pathway understanding enables new efficiencies in the identification, selection and development of optimal disease targets, biomarkers and drug candidates. Target Discovery is introducing selected technology platforms in reagent and software products and engages in discovery collaborations. The company is based in Palo Alto, California. ( www.targetdiscovery.com )

Target Discovery , Inc.
4030 Fabian Way
Palo Alto, California 94303-4607
USA

Tel: (650) 812-8100
Fax: (650) 812-8130

Industry: Pharmaceuticals, Biotechnology
Aegis Therapeutics (“Aegis”) is a specialty pharmaceutical company commercializing advanced patented drug delivery technologies that enable the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular therapeutics. Our goal is to broadly enable intranasal and transmucosal delivery of peptide and protein drugs across a wide spectrum of disease categories for the world’s current and future leading pharmaceutical and biopharmaceutical ( www.aegisthera.com )

Aegis Therapeutics LLC
16870 West Bernardo Drive Suite 390
San Diego, California 92127
USA

Tel: (858) 618-1400
Fax: (858) 618-1441

Industry: Pharmaceuticals, Biotechnology
ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is currently developing multiple DNAi-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin’s lymphoma, prostate, breast, and colon cancers. The company,s lead drug candidate, PNT-100, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi-based therapies for indications such as diabetes, Alzheimer,s and inflammatory ( www.pronai.com )

ProNAi Therapeutics , Inc.
Southwest Michigan Innovation Center 4717 Campus Drive Suite 1100
Kalamazoo, Michigan 49008
USA

Tel: (269) 372-3289
Fax: (269) 544-1079

Industry: Pharmaceuticals, Biotechnology
Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a Phase 2, drug-development company with a deep pipeline of small molecule compounds targeting the key biological processes involved in cell survival and tissue injury. Inotek was founded in 1996 and currently has 140 employees, located in its corporate headquarters and main research laboratories in Beverly, Massachusetts and its clinical operations and GMP production facilities in Israel. Inotek has developed integrated capabilities from early discovery through Phase 2 clinical ( www.inotekcorp.com )

Inotek Pharmaceuticals Corporation
Suite 419E 100 Cummings Drive
Beverly, Massachusetts 01915
USA

Tel: (978) 232-9660
Fax: (978) 232-8975

Industry: Pharmaceuticals, Biotechnology
BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow-derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons and astrocytes, as demonstrated in animal ( www.brainstorm-cell.com )

BrainStorm Cell Therapeutics Inc.
1350 Ave Of The Americas
New York, New York 10019
USA

Tel: (212) 557-9000
Fax: (212) 581-8958

Industry: Pharmaceuticals, Biotechnology
Founded in 1994, EDEN BIOSCIENCE has approximately 35 employees involved in research, sales, marketing, manufacturing and environmental stewardship. Bothell, Washington, is home to the EDEN BIOSCIENCE corporate headquarters, as well as its research and manufacturing facilities. Local sales and technical support staff is based in strategic marketing areas throughout North America and Europe, and an environmental stewardship and regulatory affairs office in Annapolis, Md. Privately held for its first six years, EDEN BIOSCIENCE raised more than $92 million in an initial public offering in September 2000. ( www.edenbio.com )

Eden Bioscience Corporation
3830 Monte Villa Parkway Suite 100
Bothell, Washington 98021-7266
USA

Tel: (425) 806-7300
Fax: (425) 806-7400

Industry: Pharmaceuticals, Biotechnology
Orion Genomics is the Second CodeÔ biotechnology company developing oncology diagnostic products and generating revenue in a hybrid products-services model. Orion’s various proprietary technologies, trademarked as GeneThresher, MethylScope, and MethylScreen, detect both normal and abnormal epigenetic patterns of genes and genomes and are used in various agricultural biotechnology and molecular diagnostic applications. Orion Genomics is located in the Center for Emerging Technologies in St. Louis. ( www.oriongenomics.com )

Orion Genomics LLC
Located In The Center For Emerging Technology 4041 Forest Park Ave
Saint Louis, Missouri 63108
USA

Tel: (314) 615-6977
Fax: (314) 615-6975

Industry: Pharmaceuticals, Biotechnology
AME is a wholly owned subsidiary of Eli Lilly and Company and a leader in applying directed molecular evolution to improve healthcare by optimizing and developing human biotherapeutics. Directed molecular evolution is a process for optimizing genes and proteins for specific commercial purposes. Since its inception, AME’s principal focus has been on applying its proprietary AMEsystem(TM) technology platform to human biotherapeutics, the largest market for directed molecular evolution. Biotherapeutics, or biopharmaceuticals, are protein pharmaceuticals such as antibodies, cytokines, hormones and enzymes. AME uses its proprietary technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. ( www.amevolution.com )

Applied Molecular Evolution , Inc.
3520 Dunhill St Ste B
San Diego, California 92121
USA

Tel: (858) 597-4990
Fax: (619) 597-4950

Industry: Pharmaceuticals, Biotechnology
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company’s HDL Therapy platform (HDL Selective Delipidation and HDL Mimetic Peptides) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary ( www.lipidsciences.com )

Lipid Sciences , Inc.
7068 Koll Center Parkway Suite 401
Pleasanton, California 94566-3111
USA

Tel: (925) 249-4000
Fax: (925) 249-4040